Advancing new vaccines against pandemic influenza in low-resource countries

Vaccine

Volumn 35, Issue 40, 2017, Pages 5397-5402

  Berlanda Scorza, Francesco ^a  

^a PATH Center for Vaccine Innovation and Access   (United States)

Author keywords

Avian influenza; H5N1; Pandemic influenza; Whole virion vaccines

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE;

ARTICLE; CAPACITY BUILDING; DRUG EFFICACY; HUMAN; INFLUENZA A (H5N1); INTERNATIONAL CAPACITY BUILDING; LICENCE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; TECHNOLOGY; VACCINE PRODUCTION; DEVELOPING COUNTRY; IMMUNOLOGY; INFLUENZA; PANDEMIC;

DEVELOPING COUNTRIES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VACCINES, ATTENUATED;

EID: 85017333605     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.03.094     Document Type: Article

References (38)

1. Nair, H., Brooks, W.A., Katz, M., Roca, A., Berkley, J.A., Madhi, S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet (Lond, Engl) 378 (2011), 1917–1930, 10.1016/S0140-6736(11)61051-9.
2. Brooks, W.A., Goswami, D., Rahman, M., Nahar, K., Fry, A.M., Balish, A., et al. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr Infect Dis J 29 (2010), 216–221, 10.1097/INF.0b013e3181bc23fd.
3. Influenza vaccines — United States, 2016–17 influenza season n.d. < http://www.cdc.gov/flu/protect/vaccine/vaccines.htm>.
4. US Centers for Disease Control and Prevention's US Outpatient Influenza-like Illness Surveillance Network – Weekly U.S. Influenza Surveillance Report n.d. < http://www.cdc.gov/flu/weekly/>.
5. Skowronski, D.M., Janjua, N.Z., De Serres, G., Sabaiduc, S., Eshaghi, A., Dickinson, J.A., et al. Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE, 9, 2014, e92153, 10.1371/journal.pone.0092153.
6. Berlanda Scorza, F., Tsvetnitsky, V., Donnelly, J.J., Universal influenza vaccines: shifting to better vaccines. Vaccine 34 (2016), 2926–2933, 10.1016/j.vaccine.2016.03.085.
7. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO n.d. < http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/>.
8. WHO. Global Action Plan for Influenza Vaccines (GAP) n.d. < http://www.who.int/influenza_vaccines_plan/en/>.
9. Murray, C.J.L., Lopez, A.D., Chin, B., Feehan, D., Hill, K.H., Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis. Lancet 368 (2006), 2211–2218, 10.1016/S0140-6736(06)69895-4.
10. PATH's Center for Vaccine Innovation and Access (CVIA) - Influenza n.d. < http://sites.path.org/cvia/our-disease-targets/influenza/>.
11. Anh, D.D., Thiem, V.D., Anh, N.T.H., Huong, V.M., Nga, N.T., Thang, T.C., et al. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults. Vaccine 34 (2016), 5457–5462, 10.1016/j.vaccine.2016.08.052.
12. Phan, T.L., Ho, V.T., Vu, M.H., Nguyen, T.N., Duong, H.T., Holt, R., et al. Clinical testing of an inactivated influenza A/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam. Vaccine 34 (2016), 5449–5456, 10.1016/j.vaccine.2016.08.055.
13. Hoa, L.K., Hiep, L.V., Be, L.V., Development of pandemic influenza vaccine production capacity in Viet Nam. Vaccine 29:Suppl 1 (2011), A34–A36, 10.1016/j.vaccine.2011.04.118.
14. Neuzil, K.M., Tsvetnitsky, V., Nyari, L.J., Bright, R.A., Boslego, J.W., PATH's Influenza Vaccine Project team. PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries. Expert Rev Vaccines 11 (2012), 939–947, 10.1586/erv.12.76.
15. Wahid, R., Holt, R., Hjorth, R., Berlanda, Scorza F., Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers. Vaccine 34 (2016), 5430–5435, 10.1016/j.vaccine.2016.07.046.
16. Donis, R.O., Ziegler, T., Chen, i.M., Davis, C.T., Foust, A., Hossain, M.J., et al. Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing. Vaccine 32 (2014), 6583–6590, 10.1016/j.vaccine.2014.06.045.
17. WHO SAGE Report of the H5N1 SAGE Working Group to the April 2009 meeting of the Strategic Advisory Group of Experts n.d. < http://www.who.int/immunization/sage/SAGE_H5N1_26Mayb.pdf>.
18. Treanor, J.J., Wilkinson, B.E., Masseoud, F., Hu-Primmer, J., Battaglia, R., O'Brien, D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 (2001), 1732–1737.
19. Keitel, W.A., Campbell, J.D., Treanor, J.J., Walter, E.B., Patel, S.M., He, F., et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 198 (2008), 1309–1316, 10.1086/592172.
20. Bart, S.A., Hohenboken, M., Della Cioppa, G., Narasimhan, V., Dormitzer, P.R., Kanesa-Thasan, N., A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med, 6, 2014, 234ra55, 10.1126/scitranslmed.300876.
21. Giudice, G., Hilbert, A., Bugarini, R., Minutello, A., Popova, O., Toneatto, D., et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24 (2006), 3063–3065, 10.1016/j.vaccine.2006.01.015.
22. Mulligan, M.J., Bernstein, D.I., Winokur, P., Rupp, R., Anderson, E., Rouphael, N., et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 312 (2014), 1409–1419, 10.1001/jama.2014.12854.
23. Rouleau, I., De Serres, G., Drolet, J.P., Skowronski, D.M., Ouakki, M., Toth, E., et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. Vaccine 31 (2013), 5989–5996, 10.1016/j.vaccine.2013.10.033.
24. Nohynek, H., Jokinen, J., Partinen, M., Vaarala, O., Kirjavainen, T., Sundman, J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE, 7, 2012, e33536, 10.1371/journal.pone.0033536.
25. Bresson, J.-L., Perronne, C., Launay, O., Gerdil, C., Saville, M., Wood, J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006), 1657–1664, 10.1016/S0140-6736(06)68656-X.
26. Leroux-Roels, I., Van der Wielen, M., Kafeja, F., Vandermeulen, C., Lazarus, R., Snape, M.D., et al. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine 27 (2009), 6918–6925, 10.1016/j.vaccine.2009.08.110.
27. Vajo, Z., Kosa, L., Szilvasy, I., Pauliny, Z., Bartha, K., Visontay, I., et al. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr Infect Dis J 27 (2008), 1052–1056, 10.1097/INF.0b013e3181861dd7.
28. van der Velden, M.V.W., Fritz, R., Pöllabauer, E.M., Portsmouth, D., Howard, M.K., Kreil, T.R., et al. Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. J Infect Dis 209 (2014), 12–23, 10.1093/infdis/jit498.
29. Bernstein, K.M., Dekker, C.L., Belshe, R., Talbot, H.K., Graham, I.L., Noah, D.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197 (2008), 667–675, 10.1086/527489.
30. Sanofi Pasteur Influenza Virus Vaccine, H5N1 n.d. < http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM112836.pdf>.
31. Rudenko, L., Naykhin, A., Donina, S., Korenkov, D., Petukhova, G., Isakova-Sivak, I., et al. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. Hum Vaccines Immunother 11 (2015), 2839–2848, 10.1080/21645515.2015.1069931.
32. Talaat, K.R., Luke, C.J., Khurana, S., Manischewitz, J., King, L.R., McMahon, B.A., et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 209 (2014), 1860–1869, 10.1093/infdis/jiu123.
33. Babu, T.M., Levine, M., Fitzgerald, T., Luke, C., Sangster, M.Y., Jin, H., et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 32 (2014), 6798–6804, 10.1016/j.vaccine.2014.09.070.
34. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2014–15 Influenza Season n.d. < http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6332a3.htm#Groups_Recommended_Vaccination_Timing_Vaccination> [accessed March 20, 2015].
35. Penttinen, P.M., Friede, M.H., Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge?. Eurosurveillance, 21, 2016, 30350, 10.2807/1560-7917.ES.2016.21.38.30350.
36. Fry, A.M., Flannery, B., Olsen, S.J., Grohskopf, L., Bresee, J., Letter to the editor: regarding the editorial by Penttinen and Friede. Eurosurveillance, 21, 2016, 30366, 10.2807/1560-7917.ES.2016.21.40.30366.
37. Nohynek, H., Baum, U., Syrjänen, R., Ikonen, N., Sundman, J., Jokinen, J., Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds – a nationwide cohort study Finland, influenza season 2015/16. Eurosurveillance, 21, 2016, 30346, 10.2807/1560-7917.ES.2016.21.38.30346.
38. Pebody, R., Warburton, F., Ellis, J., Andrews, N., Potts, A., Cottrell, S., et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Eurosurveillance, 21, 2016, 30348, 10.2807/1560-7917.ES.2016.21.38.30348.